SSKN · As filed with the SEC

STRATA Skin Sciences balance sheet, by fiscal year

The statement as STRATA Skin Sciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Consolidated Balance Sheets · USD thousands

USD thousands	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022
Assets
Current assets:
Cash and cash equivalents	7,912	7,261	6,784	5,434
Restricted cash	0	1,334	1,334	1,361
Accounts receivable, net of allowance for credit losses of $551 and $433 at December 31, 2025 and 2024, respectively	4,121	5,253	4,440	4,471
Inventories	2,814	2,246	2,673	5,547
Prepaid expenses and other current assets	753	501	312	691
Total current assets	15,600	16,595	15,543	17,504
Property and equipment, net	8,964	10,061	11,778	7,498
Operating lease right-of-use assets	920	1,264	626	975
Intangible assets, net	3,377	5,348	7,319	17,394
Goodwill	1,429	2,658	6,519	8,803
Other assets	231	231	231	98
Total assets	30,521	36,157	42,016	52,272
Liabilities and Stockholders’ Equity
Current liabilities:
Current portion of long-term debt	15,349	—	—	—
Accounts payable	2,758	2,433	3,343	3,425
Accrued expenses and other current liabilities	6,155	8,593	6,306	6,555
Deferred revenues	2,248	2,241	2,120	2,778
Current portion of operating lease liabilities	231	328	352	355
Current portion of contingent consideration	0	1,030	53	313
Total current liabilities	26,741	14,625	12,174	13,426
Long-term debt, net	0	15,192	15,044	7,476
Deferred revenues and other liabilities	184	353	552	314
Deferred tax liability	—	0	186,000	306,000
Operating lease liabilities, net of current portion	688	919	237	610
Contingent consideration, net of current portion	0	96	1,135	8,309
Total liabilities	27,613	31,185	29,328	30,441
Stockholders’ equity:
Series C convertible preferred stock, $0.10 par value; 10,000,000 shares authorized, no shares issued and outstanding	0	0	0	0
Common stock, $0.001 par value; 150,000,000 shares authorized; 5,888,199 and 4,171,161 shares issued and outstanding at December 31, 2025 and 2024, respectively	6	4	35	35
Additional paid-in capital	257,307	253,112	250,711	249,024
Accumulated deficit	(254,405)	(248,144)	(238,058)	(227,228)
Total stockholders’ equity	2,908	4,972	12,688	21,831
Total liabilities and stockholders’ equity	30,521	36,157	42,016	52,272

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.